Jan 03, 2017 12:02 pm UTC| Business
TNX-102 SL, a Phase 3 Drug candidate, recently granted Breakthrough Therapy designation by the FDA Pivotal study in military-related PTSD to begin this quarter NEW YORK, Jan. 03, 2017 -- Tonix Pharmaceuticals...
Jan 03, 2017 12:02 pm UTC| Business
TNX-102 SL, a Phase 3 Drug candidate, recently granted Breakthrough Therapy designation by the FDA Pivotal study in military-related PTSD to begin this quarter NEW YORK, Jan. 03, 2017 -- Tonix Pharmaceuticals...
Jan 03, 2017 12:02 pm UTC| Business
TNX-102 SL, a Phase 3 Drug candidate, recently granted Breakthrough Therapy designation by the FDA Pivotal study in military-related PTSD to begin this quarter NEW YORK, Jan. 03, 2017 -- Tonix Pharmaceuticals...
Quantum Materials Corp Appoints Company Founder Stephen A. Squires Chairman and CEO
Jan 03, 2017 12:02 pm UTC| Business
SAN MARCOS, Texas, Jan. 03, 2017 -- Quantum Materials Corp (OTCBB:QTMM) today announced that Quantum Materials Corp founder and Quantum Materials Asia CEO Stephen Squires has returned to helm Quantum Materials Corp as...
Quantum Materials Corp Appoints Company Founder Stephen A. Squires Chairman and CEO
Jan 03, 2017 12:02 pm UTC| Business
SAN MARCOS, Texas, Jan. 03, 2017 -- Quantum Materials Corp (OTCBB:QTMM) today announced that Quantum Materials Corp founder and Quantum Materials Asia CEO Stephen Squires has returned to helm Quantum Materials Corp as...
Quantum Materials Corp Appoints Company Founder Stephen A. Squires Chairman and CEO
Jan 03, 2017 12:02 pm UTC| Business
SAN MARCOS, Texas, Jan. 03, 2017 -- Quantum Materials Corp (OTCBB:QTMM) today announced that Quantum Materials Corp founder and Quantum Materials Asia CEO Stephen Squires has returned to helm Quantum Materials Corp as...
NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017
Jan 03, 2017 12:01 pm UTC| Business
REHOVOT, Israel, Jan. 03, 2017 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will...